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1. Introduction 
The syndrome of restless, inattentive, and impulsive behaviour known as Attention Deficit 
Hyperactivity Disorder (ADHD) or Hyperkinetic Disorder (HKD) is a common 
neurodevelopmental problem in children and adolescents. Children affected with this 
disorder are at risk of academic failure, substance abuse, and criminality in adolescence and 
adulthood. ADHD is a reflection of an underlying deficit that may have several ultimate 
causes such as genetic predisposition, psycho-physiological factors and psychological 
dysfunction, but a common pathway at the behavioural level (Hill & Cameron, 1999). By 
labelling children with difficult behaviour as suffering from a disorder, we make it easier to 
treat and this carries with it the danger of over-diagnosis (Orford, 1998). On the other hand, 
under-diagnosis is also an issue (Dopheide, 2001). 
2. Incidence 
Prevalence of ADHD estimates that 3 to 7% children would meet the criteria of Diagnostic 
and Statistical Manuel-IV (DSM-IV) of American Psychiatric Association’s diagnostic criteria 
(APA, 1994). The ratio of boys to girls is between 3:1 and 9:1 but this may decrease with age 
(Swanson et al., 1998). Part of the difference between sexes may be referral bias (Beiderman 
et al., 1996). Follow-up studies of children with ADHD find that 15% still have the full 
diagnosis at 25 years, and another 50% are in partial remission, with some symptoms 
persisting (Faraone et al., 2006). 
3. Aetiology 
No genetic marker has been identified in children with ADHD. Neuroimaging studies 
confirm abnormalities in those regions of the brain that are implicated in ADHD (Swanson 
et al., 1998; Castellanos et al., 2002). These studies report significantly smaller asymmetrical 
prefrontal and basal ganglia structures, in children with ADHD. Correlations of magnetic 
resonance imaging-based anatomical measures and specific-task performance in children 
suggest that the right prefrontal cortex is involved in inhibiting attentional and behavioural 
responses, whereas the basal ganglia seem to be involved in the execution of these responses 
(Konrad & Eickhoff, 2010). One third of affected individuals have at least one parent who 
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suffers from similar symptoms.  ADHD is also associated with low birth weight (<1500g); 
tobacco and alcohol use during pregnancy (SIGN, 2001). Although ADHD is highly 
heritable, no specific susceptibility gene has been identified (Franke et al., 2009). 
4. Symptoms 
The symptoms of ADHD are excessive and impairing levels of activity, inattention, and 
impulsiveness. Children have great difficulty remaining seated when required in structured 
situations such as in the classroom or at the dinner table. They fail to pay attention to 
instructions in academic and social situations. The difference between ADHD and normal 
behaviour is the degree of impairment. The alarming signals may be a child who is 
academically under-achieving because of his/her behaviour, despite having a normal 
intellect or a child exhibiting behaviour problems both at home and in school, which are 
considerably worse than would be expected for the standard of parenting and home 
environment. The symptoms of ADHD change through out the lifecycle. Hyperactivity and 
impulsivity may decrease as patients get older but the demands on their attention may 
increase.   
5. Assessment 
Concern about the future quality of life is heightened when parents observe their children 
struggling behaviourally at home, academically in school and socially on the playground. 
When told that a child has ADHD, parents are relieved by finding a reason for their child’s 
difficulties. The diagnosis confirms that it is not their fault. Not all children and young 
people presenting with difficult behaviour will warrant a specialist referral. This depends on 
the severity of child’s difficulties. ADHD can be provisionally diagnosed in preschool 
children but it should be confirmed after the child has started school. Some argue that 
problems with inattention, hyperactivity and impulsivity are the results of cultural 
phenomena (Block, 1977). Yet this point of view appears to be changing with the acceptance 
of ADHD as a cross-cultural disorder (Sandberg, 1996). Some children are inherently more 
inclined to be inattentive, impulsive and hyperactive than others. Such traits may run in 
families e.g. parents, siblings, and extended family members and there seems to be a genetic 
predisposition to them. Mental traits can be inherited just as height and weight. What we 
are dealing with are normal human variations that are only understood as being disorders 
when they are in conflict with cultural expectations and norms. The rating scales are an 
essential tool to obtain information but are not a substitute for a diagnosis. Reports from 
parents and teachers may not agree on the types of behaviours. This does not mean they are 
necessarily inaccurate; it may be attributed to the fact that the parents and the teachers are 
seeing the children in different settings. There are many rating scales available, most of which 
have been developed in the USA. The assessment should include information gathering. Apart 
from obtaining the completed rating scales, information should be obtained from the school 
about peer relationship and the child’s academic progress. Information is gathered about 
child’s current difficulties; family and social history; child’s developmental and medical 
history and the educational progress. While interviewing parents, one needs to obtain a 
comprehensive knowledge of each parent’s medical and psychiatric history. Family situations, 
such as a single working parent, separated or divorced parents, or reconstituted families 
where one or both parents have remarried, all affect the child.   
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5.1 Medical assessment  
Since symptoms of ADHD can occur due to a wide variety of underlying conditions, a 
comprehensive approach to the evaluation of a child with ADHD is recommended (Reiff et 
al., 1993, AACAP, 1997)). Medical assessment should include a perinatal history, 
behavioural/developmental history, family history (SIGN, 2001) and a physical examination 
for any contraindications for possible medication use, such as some cardiac dysrhythmias. 
Perinatal history should include about pregnancy and birth, maternal exposure to drugs, 
alcohol and smoking cigarettes, cannabis etc and high-risk pregnancy (e. g. prematurity, 
LBW). Behavioural/developmental history should include developmental milestones, 
difficulty engaging in quiet play and problems with obeying commands. Family History 
should include history of ADHD, drug or alcohol abuse, psychiatric illnesses, problems with 
the law, specific precipitant where symptoms can be dated, events precipitating ADHD 
symptoms such as neglect, physical or sexual abuse, parenting issues and cardiac 
arrhythmias or sudden death especially in 35 years or younger age, home Environment (key 
caregivers, frequent moves or frequent change in foster care, frequent changes of school, 
home environment and family dynamics e. g. single family, same gender partners), 
interpersonal relationship/s in the family, Poor or crowded housing. History should be 
obtained about time spent on TV-watching, computer and video games. History should also 
be obtained about peer relationships, academic under-achievement, truancy, does the child 
enjoy school, ask the school age child if she/he thinks she/he has trouble concentrating, 
review current school report as well as those from earlier years and psychometric evaluation 
by education psychologists for cognitive abilities and academic achievement levels. History 
of sleep pattern needs to be obtained.  Eating History should include appetite and eating 
habits and joining the other members for dinner. Physical examination is done to document 
a baseline growth parameters (height and weight) which should be plotted on a centile chart 
and at each follow-up visit if the child is prescribed medication, blood pressure and pulse 
rate are recorded and plotted on the centile chart, cardiac examination including 
auscultation for murmurs and femoral pulses, dysmorphic features suggestive of Fetal 
Alcohol Syndrome (FAS) or other genetic conditions, cutaneous stigmata, such as café au 
lait spots, bruising or other evidence of injury, tonsillar hypertrophy suggestive of mouth 
breathing, neurologic exam and age-appropriate mental status exam, tics, play skills 
(particularly problem solving), observing the child/parent interaction, co-ordination tasks 
and handwriting, menstrual/pubertal status in adolescents and if deemed necessary, 
psychological assessment. The assessment process should take account of the other 
conditions, which may better account for the challenging behaviour (AACAP, 1997). These 
might include medical disorders such as sleep apnoea, seizure disorders, developmental 
disorders (e. g. Intellectual disability (Learning disability, LD ), Specific Learning Difficulty 
(SpLD) formerly dyslexia and Developmental Coordination Disorder (DCP) formerly 
dyspraxia), brain injury, use of other medications (e. g. anti-epileptic drug) or sensory 
impairments; mental health disorders such as Oppositional Defiant Disorder 
(ODD)/Conduct disorder (CD), anxiety/depression, adjustment disorder, attachment 
disorder or substance abuse. Other conditions include Autism Spectrum Disorder (ASD) 
and the normal active preschool child. In addition to the history mentioned above, 
evaluation of an adolescent should also include eliciting history regarding use of alcohol 
and drugs, cigarette smoking, number of accidents and speeding tickets, sexual activity and 
spending history.  The above assessments are not indicative of ADHD but may help to rule 
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out the possibility of other under-lying medical or developmental conditions mimicking 
ADHD symptoms.  
6. Guidelines 
The guidelines for assessment and treatment have been issued by American Academy of 
Child and Adolescent Psychiatry (AACAP, 2007), the American Academy of Pediatrics 
(AAP, 2001), the European Guidelines (Taylor et al., 2004, Banaschewski et al., 2006), 
National Institute for Health and Clinical Excellence (NICE, 2008) and the Scottish 
Intercollegiate Guideline Network (SIGN, 2004). While there is a degree of consensus among 
these publications, there seems to be some international difference such as NICE 
recommends drug treatment in severe ADHD, whereas the American guidelines advice to 
start medication and later other management strategy may be considered (CADDRA, 2010).  
7. Diagnosis 
ADHD is a clinical diagnosis for which there are no tests. It is important to gather the 
information from parents/carers and school. The diagnosis is made by using the diagnosis 
criteria either of DSM –IV (APA, 2000) or ICD -10 (WHO, 1992). Both major systems of 
classification identify identical 18 symptoms (table 1). 
 
Inattention (IN) Hyperactivity (H) Impulsivity (IMP) 
Fails to attend to details Fidgets with hands or 
feet 
 
Difficulty sustaining attention Leaves seat in 
classroom 
 
Does not seem to listen Runs about or climbs  
Fails to finish Difficulty playing 
quietly 
 
Difficulty organising tasks Motor access (on the 
go, in DSM-IV) 
 
Avoids sustained effort Talks excessively 
(DSM-IV) 
Talks excessively (ICD-10) 
Loses things  Blurts out answers to 
questions 
Distracted by extraneous 
stimuli 
 Difficulty waiting turn 
Forgetful  Interrupts or intrudes on 
others 
Table 1. Symptom domains for ADHD in DSM-IV and ICD-10 
7.1 Differences between the two major diagnostic manuals (table 2) 
7.1.1 In the symptom domains of Inattention, Hyperactivity, and Impulsivity; an ICD-10 
diagnosis of HKD needs some symptoms from all three groups whereas DSM-IV ADHD 
does not, but instead specifies subtypes if symptoms are from only one domain. HKD is 
broadly similar to severe type of ADHD. 
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7.1.2 Because of the high rate of conduct disorder, ICD-10 uses the presence or absence of 
conduct disorder as the basis for the main subdivision of HKD. DSM-IV does allow the 
diagnosis of conduct disorder as a comorbid condition.   
7.1.3 Another difference between the two classifications is the use of other conditions as 
exclusion criteria. ICD-10 aims at a single diagnosis. DSM-IV aims to recognize, as many 
diagnoses as there are symptoms.   
 
HKD (ICD-10) 
Six or Six or more from IN domain, three or more from 
H domain and one or more from IMP domain. 
ADHD & subtypes (DSM-IV)  
Combined type Six or Six or more from IN domain and six or more 
from the H / IMP domain. 
Inattentive type Six or Six or more from IN domain and less than six 
from H / IMP domain+/- H / IMP less than 6 
Hyperactive/Impulsive Six or Six or more from H / IMP domain and less than 
six from IN domain. 
IN: Inattention; H: Hyperactivity; IMP: Impulsivity 
Table 2. HKD diagnosis and ADHD diagnosis subtypes 
7.2 Limitations of diagnosis criteria 
Although the DSM-IV and ICD-10 are widely used as diagnostic tools, there are a number of 
limitations (AAP, 2000).   
7.2.1 The numbers of symptoms required to make the diagnosis of ADHD / HKD does not 
vary with the severity of the symptoms or with the age. Therefore an older child with a few 
severe symptoms may not meet the diagnostic criteria, whereas a younger child with many 
less severe symptoms may meet the criteria, even though the former may experience more 
functional impairment. For a child with few severe symptoms, the diagnosis of ADHD not 
otherwise specified that is included in DSM-IV may be used, but the manual provides no 
criteria for when to make this diagnosis.  
7.2.2 The requirements that symptoms occur in at least two settings can be problematic at 
times. It may hinder the diagnosis for children who may have significant difficulties with 
attention in school but do not have problems at home. 
7.2.3 Although the criteria include symptoms be present before 7 years is useful in 
highlighting that ADHD rarely is the correct diagnosis when inattention, hyperactivity, or 
impulsivity is occurring for the first time in adolescence or in adulthood; however, it may be 
problematic in excluding children whose limited attention spans becomes more noticeable 
when they start secondary school because of increased school and home work.  
7.2.4 The terms "significant" and "some impairment" are subjective and unclear. 
7.2.5 The diagnosis is also environmentally dependent, which explains why clinicians will 
see differences in the child's behaviour between school and home settings.  
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7.2.6 It is a challenge to make a diagnosis when there are no explicit criteria for defining 
what is typical for a particular age? 
7.2.7 Currently the major diagnosis criteria are only applicable to adolescents up to 18 years 
of age. There are no diagnosis criteria for adults. 
8. Management 
Following diagnosis of ADHD, written information and available option of various 
management strategies, website addresses, and contact details of the local support groups 
should be given to the parents and the child's school regarding the condition and its 
management. Parents/carers should be informed that ADHD is a neuro-behavioural 
condition with a possible genetic aetiology which is the result of low or imbalanced levels of 
specific neurotransmitters in certain areas of the brain. Abnormally low levels of these 
neurotransmitters are associated with the impairments that are the hallmarks of ADHD. The 
need to rule out other possible diagnoses should be explained. Subsequently various 
treatment options need to be explored. Ensure that the patient and family have had an 
adequate opportunity to be educated about ADHD (CADDRA, 2010). Do ask the family to 
find out more about ADHD through reputable websites and recommended reading. They 
need to be informed of the symptoms that indicate a diagnosis and the aims and rationale 
for treatment (with an understanding that no medication eliminates all the symptoms of 
ADHD and that other strategies are also indicated as part of management). There needs to 
be a discussion of the risks and benefits of the advised therapy and the alternatives. There 
should also be discussion regarding the potential risks of no therapy. It is important to 
describe to the parents the findings obtained from the assessment, including a clear 
statement about the diagnosis and the basis on which the diagnosis is made. The family 
should be told that a copy of the clinic letter, with their consent, will be sent to the school.  
The child’s surroundings should support routines and decrease distractions. Consistent age-
appropriate limit setting is important. Retaining a positive, enjoyable relationship with their 
child improves the child’s self-esteem. Thus, doing things that the child enjoys is important. 
Parents/carers need to help the child to develop appropriate social behaviours with peers 
and adults. Whenever possible, an attempt should be made to work with both parents so 
that they are consistent with each other in their approaches. Family support should aim to 
improve relationships within the family, promote parental empowerment and develop 
strategies to manage behaviour, e.g. through a parenting group. In addition, families should 
be advised of ADHD parent support groups existing in their area. In many cases careful 
management of behaviour and advice to parents and teachers and working with the child to 
control impulsiveness and maintain concentration may be sufficient to manage the problems 
(AAP, 2001). Where these are not deemed to be sufficient, medication may be tried. Liaison 
with the school should help inform behaviour management strategies within the classroom. 
Further support from behaviour specialist teachers may be sought where necessary. The 
child’s school and the school nurse should be notified at the start of medication. Any change 
of the dosage must be notified to school and school nurse by the prescribing doctor, rather 
than simply being relayed to them by the parents or the child. Individual counselling or 
group work may be offered to the child to address issues of low self-esteem as well as to 
promote social skills and the peer relationships and offer skills in the area of anger 
management. Time should be spent with the child/young person to help them understand 
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what ADHD is and if medication is to be used, how it works and its side effects. In the more 
severe cases, and usually following behavioural interventions, a trial of medication may be 
considered. ADHD is a chronic condition requiring access to long-term treatment and 
support, sometimes over many years. However, the level and type of support needed can 
vary. The principal aims of treatment are to promote the child's development and to reduce 
secondary difficulties.  
8.1 Non psychopharmacolical interventions  
This treatment is a non-drug intervention and is recommended in mild and moderate 
degree of severity of ADHD (NICE, 2008). The therapist consults with parents and teachers 
to train them to change the learning environment for the child. It means to physically 
calming the child, to enable them to stay still, even in a group. The goal is to teach parents 
and teachers to use rewards and punishment consistently and effectively. Together with the 
therapist, the parents and teacher find rewards that will motivate the child to work. Group 
based parenting programmes can help parents/carers to develop their skills and boost 
confidence in managing challenging and difficult behaviour of their children. Some 
parenting programmes include Incredible Years, which use Webster Stratton programme for 
parents of children aged 2 – 8 years (Incredible years), Triple P for parents and the 
programme run by barnardo’s (Barnardo’s). Using effective communication skills to 
develop a loving, guiding, limit setting, consequence providing that rewards the desired 
behaviour and eliminates the undesired behaviour is the long term aim of non 
psychopharmacological intervention.  
8.2 Medications  
Advice and support about the child’s self esteem, peer group progress, academic progress 
and family relationships will also be required even if medication is used. A positive 
response to medication is not diagnostic and a good response to drugs does not validate the 
diagnosis. The presently available medications are symptomatic therapies; they are not able 
to cure the condition. Medication aims to reduce the core symptoms and to improve the 
effectiveness of other interventions. Medication treatment should focus on behavioural 
improvement and not on getting better grades in school; grades may be the net result of a 
many factors, including learning disabilities, motivation and family attitudes. 
Drugs used in the treatment of ADHD are grouped into two major categories: stimulants 
and non stimulants. Methylphenidate (MPH) and Atomoxetine (ATX) are not licensed for 
use in children less than six years of age or in adults. ATX is licensed after 6 years of age and 
may be continued in adulthood where they have been started in adolescence. 
Dexamfetamine (DEX) may be prescribed after 3 years of age. Stimulants (MPH and DEX) 
are not licensed for children with marked anxiety, agitation or tension, symptoms or family 
history of tics or Tourette’s syndrome, hyperthyroidism, angina or cardiac arrhythmia, 
glaucoma or thyrotoxicosis.   Stimulants are controlled by the Misuse of Drugs Act 1971 and 
are subject to the regulations for Controlled Drugs. For details the practitioners are advised 
to consult the European treatment guidelines (Taylor et al. 2004, Banaschewski et al, 2006). 
Parents should have been explained the advantages and disadvantages of various available 
drugs. Concerns and questions parents may have regarding both effects and side effects 
need to be addressed. An explanation of what medication can and cannot do, and what 
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other interventions are available should be given. Parents/carers should be told that not 
every medication is suitable for every patient. The guiding principle of drug intervention is 
to achieve the optimum response with the lowest dose possible that does not give side 
effects.  Therefore, start with a low dose and gradually increased until the maximum 
recommended dose level is reached or target symptoms have improved or side effects 
appear. There are recommendations for dosing for different medications in accordance with 
their licenses. Where there are comorbidities, additional or multiple medications may be 
used. The summary of product characteristics (SPC) contains specific advice about a drug.   
The most important development in ADHD occurred in 1937 with the discovery of the 
beneficial effect of DEX on attention and behaviour among children (Bradley, 1937).  The 
main breakthrough came in 1957 with the introduction of MPH and subsequently numerous 
trials confirmed safety and efficacy of stimulants (Laufer, 1971; Eisenberg, 1972). The 
mechanism of action of both the stimulants; DEX and MPH is similar; they act principally as 
inhibitors of the dopamine-uptake mechanism in the brain. DEX, in addition, promotes the 
release of this neurotransmitter, thus stimulating dopaminergic mechanisms. The stimulants 
also act on norepinephrine-containing neurones to promote an increased release of this 
monoamine. The most extensively used and researched stimulant is MPH, a derivative of 
DEX which has a rapid onset of action, short half-life. Dosage and frequency requirements 
vary with each individual child and are independent of the weight or the age. Stimulants are 
rapidly absorbed and easily cross the blood– brain barrier. If there is a lack of improvement 
or substantial side effects, another ADHD drug may be considered another (e.g., MPH vs. 
DEX). If a patient is responding well to one medication, it is advised that another medication 
should not be tried to see if there is a better response. Table 3 describes the properties of the 
ADHD drugs.  
 
Agent Onset Max effect Duration Half-life Dosage/day 
Short-acting MPH1      
MPH-IR2 20-30 min 1-2 hrs 3- 5 hrs 2-3 hrs 2.5-60 mg 
DEX3 20–60 min 1-2 hrs 6 hrs 4-6hrs 1.25-40 mg 
Long-acting MPH      
Concerta XL4,  20-30 min 2 hrs 12 hrs 3.5 hrs 18-54 mg  
Equasym XL 20-30 min 1-2 hrs 8 hrs 2 hrs 10-60mg 
Medikinet XL 20-30 min 1-2 hrs 8 hrs 2 hrs 10-60mg 
MPH-SR5 1-3 hrs 2 hrs 5-6 hrs 2-6 hrs 20-60mg 
Non stimulant      
ATX6 1 wk  1- 2 hrs 24 hrs 3.6 hrs in 
rapid 
metabolis
ers 
0.5mg/kg x 7 
days; then 
1.2mg/kg; 
max 
100mg/day 
MPH1= methylphenidate, MPH-IR2= methylphenidate-immediate release, DEX3= dexamfetamine, 
Concerta XL4= licensed up to 54 mg per day, MPH-SR5 = methylphenidate slow release, 
ATX6=atomoxetine 
Table 3. Properties of ADHD drugs.  
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8.2.1 Medications 
The license status of ADHD medications varies in the different European countries. On 
average the drugs licensed and available in different European countries are: 
Methylphenidate immediate release (IR) available as 5, 10 and 20mg tablets (5 and 20mg 
only available as Medikinet and methylphenidate tablets). 
Medikinet® XL (methylphenidate SR) available as 5, 10, 20, 30, and 40mg capsules.  
Equasym® XL (methylphenidate SR) available as 10, 20 and 30 mg capsules. 
Concerta® XL (methylphenidate SR) available as 18, 27 and 36 mg tablets. 
Dexedrine® (Dexamfetamine) available as: 5 mg tablets.  
Strattera® (atomoxetine) available as 10, 18, 25, 40, 60 and 80mg capsules. 
8.2.1.1 Methylphenidate Immediate Release (MPH IR) 
MPH is a central nervous system stimulant. The maximum recommended dosage is 0.7 mg 
per Kg per dose or 2.1 mg per Kg daily in divided doses. It is licensed from six years to 
eighteen years of age. MPH IR is active for about four hours after the last dose taken.     
8.2.1.2 Methylphenidate sustained release (MPH SR) 
Recently, there is an influx of sustained release stimulants. The first one that came in the 
market is OROS MPH, or Concerta XL (Tri-layer capsule-shaped tablets). This tablet has an 
osmotic membrane and overcoat of MPH, has two compartments for MPH, and a push 
compartment. It also has a laser-drilled hole that allows the release of medication at a pre-
specified pace. This medication was developed to replace 3 doses of immediate-release MPH 
given 4 hours apart; therefore, this drug is active for about 12 hours. The tablet shell may 
appear in the faeces 20% MPH is excreted due to an osmotic pump action and therefore 18 
mg tablet gives 15 mg IR The second MPH reformulation that came to market is marketed as 
Equasym XL which has a 30% short-acting bead, 70% long-acting bead.  It is a Biphasic 
Release Bead-Delivery System drug. This medication was designed to replace 2 doses of 
MPH. It is advised to swallow whole or empty capsule contents onto one spoonful of  apple 
sauce or similar soft food such as yoghurt The third MPH compound that came to UK 
market is called Medikinet XL. It has Bimodal Release for Once-Daily Dosing and has a 50% 
short-acting bead, 50% long-acting bead, so this medication is designed also to work for 6 to 
8 hours to cover the school day. This capsule is either swallowed whole or capsule content 
can be emptied onto one spoonful of apple sauce or similar soft food Table 4 describes the 
immediate and extended release proportions of MPH.  Ritalin slow Release (Ritalin SR) is 
not licensed in UK, but sometimes used. It is available as 20 mg tablets. 
 
Concerta XL ® Equasym XL ® Medikinet XL® 
Tablet IR 22% ER 78% Capsule IR  30% ER 70% Capsule IR 50% ER  50% 
- - - 10 mg 3 mg 7 mg 10 mg 5 mg 5 mg 
18 mg 4 mg 14 mg 20 mg 6 mg 14 mg 20 mg 10 mg 10 mg 
27 mg 6 mg 21 mg 30 mg 9 mg 21 mg 30 mg 15 mg 15 mg 
36 mg 8mg 28 mg 40 mg 812mg 28 mg 40 mg 20 mg 20 mg 
45 mg 10 mg 35 mg 50 mg 15 mg 35 mg 50 mg 25 mg 25 mg 
54 mg 12 mg 42 mg 60 mg 18 mg 42 mg 60 mg 30 mg 30 mg 
Table 4. Relative proportions of Immediate-Release (IR) and Extended-Release (ER) 
methylphenidate 
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8.2.1.3 Dexamfetamine (DEX) 
DEX is also a central nervous system stimulant. Its effect and adverse event profile are 
similar to MPH. The initial dose may be 2.5mg once or twice daily and increased if 
necessary by weekly increments of 5-10mg in the daily dose. The maximum licensed dose is 
40mg daily in divided dosage.  
8.2.1.4 Safety of stimulant medications 
Although some parents express concern that stimulants may cause drug abuse or 
dependence, a review of long-term studies of stimulants and substance abuse showed that 
drug abuse was less likely in children with ADHD who were treated with stimulants 
compared with those who were not (Wilens et al., 2003). Patients or parents/carers, who are 
at risk for substance abuse/drug-diversion, should not be prescribed short-acting stimulants 
until precautionary measures have been put. One of the most common reasons for non-
compliance is related to a lack of awareness or understanding of the side effects and lack of 
liaison between the clinician and parents. The common side-effects reported with MPH are 
insomnia, decreased appetite, pain in abdomen and headache. They are often mild and 
transient, and may be alleviated by reducing or adjusting the dosage.   Many parents 
complain that their children are 'picky eaters'. In addition, both stimulant and non-stimulant 
ADHD medication can further suppresses appetite. Moreover children with ADHD may not 
sit still long enough to finish their meals. Common sense dictates that while balanced diet is 
not likely to cure ADHD, nutritious food would improve overall health, and thus indirectly 
benefit behaviour and attention.  Unwanted effects of appetite suppression can be avoided 
by advising the drug to be taken after breakfast and lunch. Problems with sleep are a 
common complaint among ADHD patients.  A decrease in sleep quality and/or quantity 
may lead to worsening of behaviour. It is therefore important to screen for sleep difficulties. 
The acronym BEARS (Owens & Dalzell, 2008) is useful for this purpose: Bedtime resistance 
and delayed sleep onset, Excessive day time sleepiness, Awakenings during night, 
Regularity, pattern and duration of sleep and Snoring and other symptoms of sleep-
disordered breathing. The causes of sleep problems include anxiety, ODD, sleep disorders 
(Obstructive Sleep Apnoea, Delayed Sleep Phase Syndrome (DSPS) and Restless Leg 
Syndrome). Stimulants may increase the difficulty of falling asleep. In DSPS, teenager falls 
asleep later than the expected time, has a normal sleep at night but wakes up late the next 
day. Sleep is optimized by maintaining a quiet and comfortable sleep environment. 
Exposures to TV, computer games or internet chat lines disrupt the initiation of sleep. The 
bed is not for watching TV, eating, or doing homework. No vigorous exercise within two 
hours of bedtime is recommended.  Avoid drinks containing caffeine such as chocolate, 
coffee, tea and cola in the late afternoon and evening and advice a bath before bed to help 
relax. Melatonin is a natural hormone produced by the pineal gland in the brain. It is a sleep 
inducer and helps to fall asleep at night. Certain foods are rich in melatonin such as oats, 
rice, sweet corn, barley and tomatoes. Melatonin 2-10 mg may be administered 30-60 
minutes before the bedtime for children with significant difficulty getting to sleep.  There is 
evidence that melatonin is safe with short term use, but additional studies are needed to 
determine its long term safety (Buscemi et al. 2006). A very rare but important adverse 
reaction is bone marrow suppression.  A routine full blood count is not warranted unless 
there is a clinical indication. The most commonly reported adverse effects with ATX are 
appetite decrease, headache, somnolence, nausea, vomiting and abdominal pain.  Hostility 
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(predominantly aggression, oppositional behaviour and anger) is an uncommon adverse effect 
with ATX. Aggression is a common side-effect of stimulants. Stimulants are advised to avoid 
in those with suicidal tendency and suicidal ideation, although suicidal attempt (including 
completed suicide) is very rare. Patients with emergent suicidal ideation or behaviour during 
treatment should be evaluated immediately by their physician. Patients on ATX should be 
closely monitored for the appearance or worsening of aggressive behaviour, hostility or 
emotional lability. A full list of potential adverse effects is listed in the summary of product 
characteristic (SPC) of individual drugs. They are also available online on the Electronic 
Medicines Compendium website (http://www.medicines.org.uk/emc/). Side effects which 
may warrant dose omission until discussed with an ADHD specialist include raised blood 
pressure, increase in seizure frequency in patients with epilepsy, heart rhythm changes, 
blurred eyesight or evidence of rare blood disorders. Anxiety is a commonly occurring 
adverse event with MPH. Clinical evaluation for anxiety or agitation should precede use of 
MPH and patients should be regularly monitored for the emergence or worsening of these 
symptoms regularly. A caution is needed to use ADHD drugs in women of childbearing age 
as effects of ADHD medications on the foetus and on breast-feeding are unknown. As per 
the SPC, ATX or MHP should not be used during pregnancy unless the benefit outweighs 
the risk and DEX is contra-indicated in pregnancy and during lactation. Full list of 
precautions / contra-indications are included in the SPC. ATX should be discontinued in 
patients with jaundice or laboratory evidence of liver injury. Very rarely, liver toxicity with 
elevated hepatic enzymes and bilirubin has been reported. Uses of all ADHD medications 
with MAOIs are contraindicated. It is good practice to explain to a teenager about the 
condition and the option of various drugs to gain her/his confidence. The use of 
medications may protect them from poor social skills. Combining medications for ADHD 
with illicit drugs or alcohol could be dangerous as the effects may be exaggerated.  
8.2.1.5 Is there any tolerance to stimulants? 
Acute tolerance, or tachyphylaxis means in order to maintain the response in the neuron, we 
need to increase the concentration of medication to maintain the response. In fact, two of the 
available stimulants, Concerta XL and Equasym XL, use the principle of what's called an 
ascending curve, meaning that the concentration of MPH goes up across the day to 
counteract acute tolerance. So the concentration rises across the day. Thus the issue of acute 
tachyphylaxis has been considered in the development of some of the compounds available 
today. 
8.2.1.6 Non-stimulant 
Atomoxetine hydrochloride (ATX) is a non stimulant drug with no abuse potential and is 
effective for 24 hours. It is a selective inhibitor of noradrenaline reuptake licensed for the 
treatment of ADHD in children aged 6 years and older, adolescents and adults. It may be 
useful in children who do not respond or develop severe side effects to stimulants. Certain 
situations such as comorbidity with tics, Tourette’s syndrome or substance abuse would 
support ATX as a first line option. It is available as Strattera® 10, 18, 25, 40, 60 & 80 mg 
capsules. The recommended starting dose in six years or older and adolescents with body 
weight up to 70kg is 0.5 mg/kg/day (the dosing is weight based). The initial dose should be 
maintained for a minimum of 7 days prior to upward dose titration according to clinical 
response and tolerability.  The dose is usually administered as a single daily dose but can 
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also be given in two dived doses. The maintenance dose is 1.2mg/kg/day (depending on 
the available dosage strengths). No additional benefit has been demonstrated for doses 
higher than 1.2mg/kg/day.  The plasma half-life is 3.6 hours in extensive metabolizers and 
21 hours in poor metabolizers. It is not a schedule II drug. Strattera has been studied in trials 
involving over 4000 children and adolescents with ADHD. Peak efficacy occurs between 2 
and 6 weeks after initiation, in contrast to the stimulants, which provide a response within 
hours. It is safe, well tolerated, and effective in 6 published trials in children and adolescents 
(Corman et al., 2004). Labelling for ATX includes "Black Box" warning for severe liver injury 
since February 2005, and for suicidality since November 2005, both of which reflect a pooled 
analysis of short-term placebo-controlled clinical trials found an average risk of suicidal 
ideation of 0.4% of children and adolescents (Wooltorton, 2005). Although uncommon, 
suicidal ideation is reported to be significantly more frequent in paediatric ADHD patients 
treated with ATX compared to those treated with placebo (Bangs et al., 2008).    
8.2.1.7 Choosing between stimulant and nonstimulant drug 
Tasks that require mental effort change over the years. In childhood there may only be a 
need to treat during daytime while in adolescents, the need to cover the evenings may be 
necessary. This may be critical for tasks such as driving. When selecting stimulants Vs non-
stimulants, it is helpful to assess and compare the different side effect profiles. Another 
consideration when choosing a drug category is the onset of action. When patients require 
rapid response, stimulants are the treatments of choice. Non stimulant may require two to 
six weeks to show a treatment response. MPH/ DEX/ATX dependence is not a problem in 
the drug therapy of ADHD. 
8.2.2 Monitoring 
Heart rate, blood pressure, height and weight should be checked regularly and recorded on 
a growth chart. Drug related side effects should be checked at each clinic visit. Blood tests 
should not be viewed as routine. Patients and their families/carers need to be educated 
about ADHD and prescribed drug. Biases against the use of ADHD medications are often 
due to misinformation regarding side effects. Alternatively, parents/carers may have 
excessive expectation from the drug therapy which may lead to disappointment. It is 
important to inform parents/carers that medication is a part of the holistic approach to the 
management of ADHD. Obtain the completed rating scales to monitor treatment response. 
Advice the parents to stop the medication during weekends and during school holidays if 
growth appears to be adversely affected. A telephone call may be beneficial to follow up the 
prescribed ADHD medication.  Once a stable optimal dose has been determined, the ideal 
medication follow-up is six months. Non-compliance to treatment may be related to lack of 
frequency of follow-up. A monitoring form such as in appendix 1 may be used in the clinics. 
8.2.3 Polypharmacy  
When a clinician feels that a second medication is needed, it is advised to begin with an 
ADHD medication that is known to combine safely with the second medication. For 
example, in the selection of an ADHD medication for a patient with severe conduct disorder 
and aggressive behaviour, a psychostimulant could be combined with an atypical 
antipsychotic (Turgay, 2005). MPH SPC has a caution around this combination. Some of the 
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side effects related to drug interaction occur because of competition for liver enzymes that 
metabolise the drug. MPH increases plasma concentrations of phenytoin and delays 
intestinal absorption of phenytoin, phenobarbitone and ethosuximide. MPH inhibits 
metabolism of tricyclic antidepressants and warfarin. ATX can be combined with stimulants 
to augment the effect in the case that the clinician feels the patient has not achieved an 
adequate response (Wilens et al., 2009). Such a combination should be initiated by a clinician 
with specialization in ADHD. The combinations of ADHD drugs are used sometimes in 
clinical practice although it is not recommended. Results from the handful of studies suggest 
that combining stimulant therapy with nonstimulant alternatives may result in more 
significant symptom reductions in patients for whom monotherapy is less than optimal. 
There are no studies to suggest that combing stimulant with a non-stimulant increases the 
risk of cardiac side-effects. Combination usage of stimulant and non-stimulant is not 
included in the SPCs and hence appropriate safety and efficacy have not been determined.    
8.2.4 Length of treatment  
Many children will need to be on medication for years, hence the need to be clear about the 
diagnosis and review the diagnosis if required. 
8.2.5 Compliance 
Between a third and a half of medicines that are prescribed for long-term conditions are not 
used as recommended (NICE, 2009). Psychoeducation is the most useful means of ensuring 
compliance. The aim should be to get the adolescent to take responsibility for his/her own 
medications. Parents involvement may be necessary to ensure that medication is taken as 
scheduled. Once-daily dosing improves compliance. 
8.3 Non psychopharmacological interventions 
ADHD patients may take longer time to integrate socially acceptable habits into their lives. 
They are at significant risk of being involved with bullying as a bully, as a victim or both. 
The key factor is to create a positive environment that motivates the individual. When 
families are reluctant to use medications or there are side-effects behavioural treatments 
alone can be a viable alternative, provided that both parents and teachers are willing to 
undertake the effort required. National Institute for Health and Clinical excellence (NICE) 
recommends group parent training for ADHD with moderate levels of impairment (NICE, 
2008). Parents/carers should be informed that children with ADHD may have additional 
social, academic, and emotional problems. Interventions such as additional help in academic 
work, social skills training, individual psychotherapy, parent training, family therapy or 
explaining to the child about ADHD, removing guilt, low self-esteem may be needed for the 
child and family. 
8.4 Practice point   
Make sure to review the child’s strengths, not just his/her areas of weaknesses. This 
establishes a rapport with the child and family that makes future visits easier and can aid 
intervention planning. If there are any signs or symptoms of a physical illness that may be a 
factor in explaining the clinical symptoms, this takes precedence in the evaluation. Begin the 
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interview by talking about the child’s strengths. Ask the child to draw a picture of 
themselves and then their family on the same page. This helps to determine the child’s 
perspective of the family. Note any unusual perceptual differences like drawing themselves 
bigger than the parents. Make appropriate referral if one or both of the parents need an 
assessment for ADHD or other psychiatric disturbance if it appears evident.  
9. Treatment consideration in common comorbidities 
It is estimated that at least 65% of children with ADHD have one or more comorbid 
conditions (Biederman et al., 1991). When there is a comorbid psychiatric disorder, it is 
generally advised that the ADHD should be treated first. However, if comorbidity puts the 
patient at risk for harm to others or to himself/herself, then this comorbidity takes 
precedence for treatment.   
9.1 Oppositional Defiant Disorder (ODD)  
In childhood, the most common comorbid disorder is ODD in as many as 40% of ADHD 
children (Taylor et al., 2004). ODD is characterized by the child’s inability to accept parental 
authority and the strong need to be in control. Distinguishing between normal adolescent 
self-assertion and ODD may not always be easy. Treatment of the ADHD may not resolve 
all ODD symptomatology. Strategies leading to positive reinforcement and targeting 
positive goals are often useful. Use of time-out and appropriate strategies that are applied 
with consistency also help to deal with the oppositional defiance. Behavioural interventions 
are effective, but they need to be consistent and ongoing.  
9.2 Conduct Disorder (CD)  
The risk for the development of CD in children with both ADHD and ODD is two to three 
times greater (Barkley, 2004). Behavioural interventions are necessary for this disorder. 
Comorbid CD also puts children at risk for gravitating towards other children with similar 
problems. Strategies that promote positive peer relationships and effective empathy 
development are indicated. A medication trial may be advised in conjunction with 
comprehensive psychosocial treatment.  
9.3 Intellectual Disability (Learning Disability, LD)  
Children with ADHD frequently fall below control groups on standardised achievement 
tests (Barkley et al., 1990). Children with ADHD often have weaknesses in the cognitive 
areas of executive functioning, working memory and processing speed. If LD is 
documented, it may need more one to one support for the age-appropriate educational 
progress.  Children and adolescents with an IQ less than 50 should not ordinarily be 
prescribed stimulants as they are usually sensitive to the side effects.   
9.4 Aggression  
Verbal and physical aggression is not uncommon in ADHD. The most common reason why 
children with ADHD would act aggressively is a combination of ADHD with either ODD or 
CD. Treating the ADHD is usually the first step. However, aggression might be part of 
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another diagnosis. Behavioural interventions and all ADHD medications may decrease 
aggressive behaviour. If needed, new generation antipsychotic medications can be tried. A 
study has shown that risperidone is effective in controlling ADHD, ODD and CD (Aman et 
al., 2004). Monitoring of metabolic changes, weight gain, and extra-pyramidal side effects 
are necessary if an antipsychotic is used.  
9.5 Bipolar Disorder (BD)  
This is an uncommon disorder in childhood. BD should be considered as the primary 
diagnosis if there are prominent, episodic, cycling mood symptoms. BD may be suggested 
by a strong family history of BD or depression and paradoxical response to stimulants 
(worsening of mood or rage symptoms).If BD is suspected, referral to a Child and 
Adolescent Psychiatrist is recommended (CADDRA, 2010). 
9.6 Pervasive Developmental Disorder (PDD)  
PDD presents with difficulties in social communication, social interaction and 
stereotyped, repetitive behaviour. Clinical symptoms of PDD supersede that of ADHD 
and should be the primary diagnosis and can co-exist. The FDA recently approved the use 
of risperidone in controlling aggressive and self-injurious behaviour and irritability 
(Taylor et al., 2004).    
9.7 Depression 
Many patients with depression may present with transitional inattention, short-term 
memory problems, irritability and impulsivity (Voeller, 2004). When the depression is 
associated with problem in the social environment, treatment strategies include individual 
and family therapy. Stimulants may produce a mild antidepressant effect in some patients, 
while they may worsen mood in others. All of the drugs used to treat ADHD have the 
potential to unmask a mood disorder or to cause mood symptoms. 
9.8 Anxiety  
Anxiety in ADHD can manifest as Generalized Anxiety Disorder, Social Phobia, Separation 
Anxiety Disorder, Post Traumatic Stress Disorder (PTSD) or Obsessive-Compulsive 
Disorder (OCD). PTSD may be a misdiagnosed as ADHD as there are similar symptom 
complex. PTSD is likely if there is no clear family history of ADHD or pre-morbid 
symptoms of ADHD prior to the traumatic situation.  
9.9 Tic disorders  
Stimulant medications can be used to treat ADHD with tic disorders, but caution should be 
exercised as tics may be exacerbated in some children. If tics appear with stimulants, 
consider lowering amount/discontinue or change to a non stimulant. The MPH SPC has 
warnings for tics and anxiety. There are currently no warnings relating to the use of 
atomoxetine in tics or anxiety. If OCD exists then the combination with ADHD may be part 
of a Tic Disorder (e.g., Tourette’s syndrome) so it is important to look for motor and phonic 
tics.  
www.intechopen.com
 
Current Directions in ADHD and Its Treatment 
 
18
9.10 Epilepsy 
Seizure control is first priority as numbers of seizures are directly related to processing and 
attention difficulties. Structural abnormality in brain is probably a risk factor for epilepsy 
with comorbid ADHD. Moreover uncontrolled seizures cause disturbed sleep, which in turn 
may result in attention difficulties during the day. Side effects of some anti epileptic drugs 
such as topiramate, vigabatrin, gabapentine are known to increase aggression in LD and 
many children with epilepsy are likely to have LD. Stimulants seem to be safe in children 
with well controlled seizures. ADHD children are more prone for unprovoked 
seizures then the normal population (Hersdorffern et al., 2004). The SPC for MPH state it 
may lower the convulsive threshold in patients with prior history of seizures and in patients 
with prior EEG abnormalities.    
9.11 Substance Use/Abuse Disorder (SUD)  
ADHD patients are at increased risk of using illicit substances. It is essential that a history 
for substance abuse is explored with the individual alone. Ask whether their friends use 
drugs or alcohol. A positive response suggests they are likely to be at high risk for substance 
use. By treating ADHD, there is better outcome in comorbid SUD.  
10. Cardiac risks of drugs 
Sudden death with ADHD medications is very similar to those with sudden death in the 
general population. Structural heart diseases, history of syncope, family history of sudden 
death/exercise induced sudden death are clues, which can help to suspect a higher risk. The 
usefulness of ECG screening in patients being treated with drugs is unknown. The small but 
unproven potential contribution of ADHD drugs to the rare incidence of sudden death in 
children must be weighed against the clinical benefit of the medication. In a child or 
adolescent with ADHD, who has no cardiac symptoms, the risk of cardiac adverse events 
from ADHD medications is very low. The American Heart Association Recommends (Vetter 
et al., 2008) that before therapy with psychotherapeutic agents is initiated, a careful history 
should be obtained with special attention to fainting or dizziness particularly with exercise, 
complaint of chest pain or shortness of breath with exercise and about seizures. The family 
history should focus on the long QT syndrome, sudden cardiac death or heart attack in 
members below 35 years of age and history of Marfan syndrome. Presence of these 
symptoms/risk factors warrants a cardiovascular evaluation by a cardiologist before 
initiation of drug. Patients should be asked the occurrence of any of the cardiac symptoms 
during the follow up visits. The physical examination should include checking heart rate 
and blood pressure.  
11. Complimentary and Alternative Medicine (CAM) in ADHD 
Over the years, a great deal of media attention has focused on diets for treatment of ADHD. 
Some suggested a “few foods” approach elimination diet if psychological interventions are 
not effective (Carter et al., 1993; Hill & Taylor, 2001). Most of these dietary manipulations 
involve eliminating additives (Feingold diet) and foods incriminated to increase 
hyperactivity, such as sugar, chocolate and caffeine or common food allergens such as 
wheat, milk and eggs. Several double-blind placebo-controlled studies have failed to 
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support beneficial effect of dietary manipulation on the behaviour, except possibly in a very 
small percentage of children (Egger et al., 1992; Wolraich et al., 1995).  Few studies have 
reported behavioural improvement with hypoallergenic diets (Kaplan et al., 1989; Egger et 
al., 1992; Boris et al., 1994). The results of these studies require further replication before 
dietary intervention can be considered efficacious. A working group of the American 
Academy of Child and Adolescent Psychiatry has stated “Given the minimal evidence of 
efficacy and extreme difficulty of inducing children and adolescents to comply with 
restricted diet, they should not be recommended (AACAP, 1997). Current evidence suggest 
that diets are arduous to implement and some may be nutritionally deficient (DTB, 1995) 
and a restriction or elimination of diet in children with ADHD is not recommended (SIGN, 
2001). The available best evidence practice is that a response to food may show change in 
mood state (irritability) rather than ADHD symptoms per se. An additive-free diet, low in 
sugar, and avoiding foods that are suspected of exacerbating symptoms is often tried by 
families to help improve ADHD symptoms. As long as needs for essential nutrients are 
met, these diets are safe, although their effectiveness in individual children is difficult to 
predict.  
12. Long term outcomes  
It was thought that hyperactivity simply goes away by adolescence. Although 
hyperactivity lessens with time but it is often replaced by problems of antisocial 
behaviour. There appears to be three different patterns of outcomes- resolution of 
symptoms in young adulthood in about 30%, persistence of some symptoms in about 40% 
and severe dysfunction associated with persistent symptoms, substance abuse and 
antisocial behaviour in 30% (Cantwell, 1996). A prospective study in London community 
survey found that hyperactive behaviour was a strong risk factor for later psychiatric 
diagnosis, antisocial behaviour, and social and peer problems, even after allowing for a 
coexistent CD (Taylor et al. 1996).   
13. Summary 
ADHD is a persistent and impairing disorder. Although its origin is uncertain, biological, 
psychological, and social factors are implicated. The first step in the management is accurate 
diagnosis. Behavioural modification and educational approaches are strategies of first 
choice. Medication can provide respite from the symptoms during which time other 
essential aspects of therapy can be implemented. Advice and support about behaviour 
management and attention to the child’s self esteem, peer group interaction, academic 
progress and family relationships are required even if medication is used. Children with 
ADHD are cared for at home. Parents are both part of the team and carer for the child and 
the family needs care themselves. As their child’s primary carers, they must be included in 
the decision of any treatment plans. Some parents collect endless opinions. Sometimes the 
initial counselling or diagnosis was inadequate and questions that could have been 
answered were ignored or sidestepped. There are many parents who want specific advice 
on what more they themselves can do to help the child. For parents of an ADHD child, the 
number of possible interventions can be extremely confusing. They are likely to hear about a 
host of treatment options that lack scientific support.  
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14. Key points 
 ADHD is a common behavioural disorder with clear diagnosis criteria. 
 ADHD co-exists with other conditions in a high proportion.  
 Treatment options for ADHD include behaviour management, medications and 
educational modification. 
 Early recognition and treatment of ADHD may result in less antisocial behaviour, 
criminality and substance abuse in later life.  
15. Appendix 1.  
 
 
Side-effects Questionnaire (parents/carers) 
Child’s Name: ___________________________D O B: _____________ Date: ________________ 
All medication has side-effects; some are more troublesome than others.  We want to make 
sure that children who are taking medication do not suffer.  
For each item, please tick on each line how much that statement applies to your child over 
the last seven days according to your own observations 
0 is not at all 
1 is a few occasions only 
2 is about half the time 
3 is most of the time 
4 is all the time 
 
Symptom 0  1 2 3 4  
Talks less than usual       
Poor appetite      
Irritable      
Complains of stomach ache      
Complains of headache      
Drowsy      
Looks sad, miserable      
Looks anxious      
Seems unsteady      
Excited      
Angry      
Has nightmares      
Displays twitches (tics)      
 
Is there anything else you would like to add? 
______________________________________________________________________________ 
______________________________________________________________________________ 
Thank you very much 
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